Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from Stoke Therapeutics.
Preview: Real Madrid vs. Man City - prediction, team news, lineups Preview: Scotland vs. Ireland - prediction, team news, lineups Preview: Italy vs. Wales ...
Dyne Therapeutics Inc.-0.93% $1.42B ...
After hours: February 21 at 5:44:39 PM EST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback